Columbia University is one of the leading programs in the United States conducting a groundbreaking Phase 2 clinical trial of an investigational gene therapy for dry age-related macular degeneration.

NewYork-Presbyterian obstetricians and gynecologists continue to investigate COVID-19 and its potential impact on pregnancy outcomes, including studies on serial testing for SARS-CoV-2 and vaccinations.

Neurologists and critical care medicine specialists at NewYork-Presbyterian Hospital offer highly specialized expertise in disorders of consciousness to promote the best outcomes for patients.

Physical medicine and rehabilitation specialists at NewYork-Presbyterian Hospital present recent updates on novel devices to improve recovery for patients living with the after-effects of stroke.

Oncologists and other specialists at NewYork-Presbyterian Hospital continue to contribute their expertise and resources to scientific investigations of COVID-19 and its implications for oncology care.

Research by Adam Mor, MD, PhD, a rheumatologist and molecular immunologist at NewYork-Presbyterian/Columbia University Irving Medical Center, focuses on the function of T lymphocytes in autoimmune disease and cancer

Research sites work collaboratively to define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of rheumatoid arthritis, lupus, and related autoimmune diseases.

In the rapidly evolving field of cardio-oncology, NewYork-Presbyterian Hospital is making its mark with dedicated programs led by cardiology faculty at Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine.